focus -WSS

focus

author：entertainment 2025-09-07 13:57:47 - browse：9

Photograph of Bill Cassidy. -- health policy coverage from STAT — Sen. Bill Cassidy (R-La.) Kevin Dietsch/Getty Images

WASHINGTON — With Novo Nordisk’s Wegovy and Ozempic hitting blockbuster sales and a new rival approved this week, everyone in Washington is thinking about how to manage the crashing wave of weight loss drug costs.

The explosive national demand for weight management therapies and diabetes drugs like Ozempic — all of which are indicated for indefinite use — has become central in an ongoing policy debate over high drug costs and controversial tactics to manage them, including President Biden’s plan to let the government negotiate directly with pharmaceutical companies. Seventy percent of Americans could qualify for these medicines.

Sen. Bill Cassidy (R-La.), the highest-ranking Republican on the Senate’s health policy committee, has vehemently opposed the negotiation plan, arguing it reduces incentives to develop new therapies and may not actually reduce patients’ costs.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies
Next article： Chimpanzees, like humans and whales, get menopause: Study

hotspot

focus

WSS

Biden's order seeks to regulate AI risk without stifling innovation

FDA has safety concerns on CRISPR

FDA has safety concerns on CRISPR

STAT Summit: Meghan O’Rourke on making chronic illness visible

Roivant's CEO is a star, but biotech's black hole persists

Questions loom on AstraZeneca cancer drug as safety concerns ebb

focus

focus

leisure time

23andMe had bad news about my health. I wish a person had delivered it

Study on Amgen’s bispecific immunotherapy produces positive data

Duchenne breakthrough therapy leaves behind pioneering families

Maker of FluMist seeks to allow at

Dobbs anniversary: the lost opportunity of abortion as health care

Readout Newsletter: XBI biotech index, Akero Therapeutics

Malaria cases in Florida and Texas: Here’s what you need to know

STAT Readout: Friday, Oct. 20 biotech updates

In Memoriam: Notable people who died in 2023

Readout Newsletter: The latest from Bristol, Sarepta, and Novartis

hotspot

The pink breast cancer awareness ribbon needs a redesign

The future of Biogen: Pragmatism, ‘moonshots,’ and no Twinkies

FDA approves Eli Lilly ulcerative colitis treatment Omvoh

Meta's Zuckerberg and Chan on track to put $50 billion into science

Merck, Daiichi strike cancer drug pact worth up to $22 billion

WHO may add ‘noma' to its list of neglected tropical diseases

leisure time

hotspot

focus

Wikipedia